Video

Outcomes show high rates of penile curvature improvement after CCH injections

Author(s):

Urology Times staff
Conference|SMSNA Meeting

In this video, Matthew J. Ziegelmann, MD, discusses the findings of the study, “Collagenase clostridium histolyticum treatment for Peyronie’s disease: analysis of outcomes and cumulative benefits after each injection cycle,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Ziegelmann is a urologist at the Mayo Clinic, Rochester, Minnesota.

Related Videos
Related Content
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
June 9th 2025

Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

Hannah Clarke
The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
June 5th 2025

Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

Hannah Clarke
According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
Amy L. Shaver, PhD, PharmD, MPH
June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor
In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
June 4th 2025

Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

Hannah Clarke
“AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
© 2025 MJH Life Sciences

All rights reserved.